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Summary. Acinetobacter baumannii origin and its epidemiology is under a great concern worldwide since this microorganism 
has become a leading nosocomial pathogen of the 21th century among the “ESKAPE“ group of microorganisms. The aim of the 
study was to monitor and explore the epidemiology of this important hospital pathogen in the second largest clinical university 
hospital in Croatia. The presence of A. baumannii in hospital wastewater, as a route for possible transmission outside of the hospital 
setting, as well as its survival in environmental conditions including seawater, was investigated. During the examination period, 
ten both carbapenem and multidrug-resistant isolates of A. baumannii were recovered from hospital wastewater and compared 
to the clinical isolates originating from the same monitoring period. Multiplex PCR confirmed that four wastewater isolates 
harboured blaOXA-23-like, while five wastewater isolates harboured blaOXA-40-like genes sharing 100% sequence identity with blaOXA-72 
sequence described in the same hospital in 2009, confirming the presence of an endemic cluster. Survival of A. baumannii in 
natural seawater was examined during 50 days of monitoring and to the best of our knowledge, was performed for the first time. 
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Introduction
Among the “ESKAPE” pathogens, Acinetobacter bauman-
nii is the most frequently encountered microorganism in the 
hospital setting causing serious infections, especially in the 
intensive care units. As a leading nosocomial pathogen of 
the 21st century, having the ability to acquire resistance to 
almost all antimicrobial agents, origin and epidemiology 
of this emerging hospital pathogen is under a great concern 
worldwide [15]. 
A. baumannii can cause various infections like nosocomial 
pneumonia, bacteraemia, meningitis, skin and soft tissue, and 
urinary tract infections. The incidence of serious infections 
(blood steam infections and ventilator-associated pneumonia) 
caused by multidrug-resistant A. baumannii ranges between 
47% and 93%, with mortality rates between 30% and 70% [2]. 
University Hospital of Split (UHS) is the leading medical 
centre with 1400 beds in the Southern Croatia and is situated on 
two locations (500 m distance) in the middle of Adriatic coast. 
Hospital wastewaters are discharged without any pre-treatment 
into the combined urban sewage system. The urban sewage 
undergoes the mechanical treatment through the coarse screens 
and is afterwards discharged into the Adriatic Sea.
 Since 2009, UHS has a growing problem in the number 
of infections caused by carbapenem-resistant isolates of A. 
baumannii, which is now almost endemically present in most 
of the intensive care units inside the hospital [7,8]. The coop-
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eration with Croatian Committee for Antibiotic Resistance 
Surveillance (CARS) of the Croatian Academy of Medical 
Sciences (CAMS) for the monitoring of sensitivity and resist-
ance of clinical isolates of A. baumannii was established in the 
last decade. According to recently published data, during the 
last three months in 2015, a total of 120 clinical isolates of A. 
baumannii were isolated from hospitalized patients in UHS, 
mainly from respiratory samples in intensive care units [16]. 
In the last decade, the resistance rates of A. baumannii to car-
bapenems in UHS have increased significantly, from 10 % in 
the 2006 to almost 97% in 2016 [16]. Besides hospital-acquired 
infections, community-acquired A. baumannii infections, par-
ticularly pneumonia in tropical regions of the world, have been 
recently described [4,1]. Therefore, the aim of the study was to 
monitor and explore the epidemiology of this important hospital 
pathogen in Croatia. The presence of A. baumannii in hospital 
wastewater as a route for possible transmission outside of the 
hospital setting, as well as survival of this pathogen outside the 
hospital environment was investigated. 
Material and methods
Isolation and characterization of A. baumannii 
isolates. Samples of wastewater were collected from the Uni-
versity Hospital of Split (UHS), situated at two locations (A and 
B) in the town of Split. Wastewater was sampled for five times, in 
the period from October 2014 until April 2015, on both locations. 
The samples were taken in 500 ml sterile bottles and processed 
within two hours. They were diluted in sterile peptone water 
and filtered through membrane filters of pore size 0.45 µm. The 
filters were placed on CHROMagar Acinetobacter supplemented 
with CR102 (CHROMagar) and 15 mg/L of cefsulodin sodium 
salt hydrate (Sigma-Aldrich) [13]. The plates were incubated at 
42°C/48 h. Presumptive colonies of A. baumannii were reculti-
vated (42°C/24 h) on the same selective plates and afterwards on 
nutrient agar. Identification of A. baumannii was performed by 
routine bacteriological techniques and confirmed by matrix-as-
sisted laser desorption ionization-time of flight mass spectrom-
etry - MALDI-TOF MS (software version 3.0, Microflex LT, 
Bruker Daltonics) on cell extracts [18]. Antibiotic susceptibility 
was assessed by disk diffusion method. The MICs values were 
confirmed by Vitek2 system or gradient E-tests (AB Biodisk), 
and interpreted according to the EUCAST criteria, except for 
ampicillin/sulbactam and tigecycline [3,5]. 
Molecular characterization of A. baumannii iso-
lates. The relatedness of isolated A. baumannii to clinical 
isolates was assessed by using pulsed-field gel electrophoresis 
(PFGE). The PFGE results of A. baumannii isolates recovered 
from the wastewater were compared to four clinical isolates col-
lected from routine surveillance cultures and respiratory samples 
(tracheal aspirates) of patients in Intensive Care Units (ICUs) of 
UHS during October 2015 and April 2016. PFGE analysis was 
performed using CHEF-DRII/III system (Bio-Rad) with ApaI 
(New England BioLabs) and Salmonella serotype Braenderup 
strain H9812 as marker. The images of gel-electrophoresed 
restriction products were processed using Gel-Doc 1000 system 
(Bio-Rad) and Compar software. PFGE profiles were analysed 
and compared using Molecular Analyst Software for Fingerprint-
ing (Bio-Rad). Dendogram was created with the unweighted pair 
group method with arithmetic averages analysis (UPGMA) using 
Dice similarity coefficient with optimisation and a position tol-
erance of 1.5%. The isolates were classified into clusters based 
on their genetic similarity (cut-off of ≥ 90%). The presence of 
genes of blaOXA lineage, which encode OXA-type carbapenemas-
es, was further confirmed in selected A. baumannii strains, based 
on PFGE patterns and antibiotic susceptibility profiles. Multi-
plex PCR was used to amplify blaOXA-51-like, blaOXA-40-like, blaOXA-
23-like and blaOXA-58-likegenes, according to Woodford et al [22]. In 
the same PCR reaction, primers for blaOXA-143-like were added, 
according to Higgins [12]. All obtained amplicons of blaOXA 
genes were sequenced on both strands (commercial service Mac-
rogen Europe, the Netherlands). Raw nucleotide sequences were 
assembly and manual editing using SequencherTM 4.7 software 
(http://www.genecodes.com/). Together with available sequences 
retrieved from the Genbank, blaOXA sequences obtained in the 
scope of this study were aligned with ClustalX 2.0 [19]. Subse-
quent phylogenetic analyses were performed by using MEGA 
7 software [14], with neighbour-joining method and number of 
differences model. In order to estimate the stability of nodes and 
to support the inferred clades, bootstrap analyses of 500 repli-
cates were performed.
Survival of Acinetobacter baumannii in sea-
water. Survival of A. baumannii in natural seawater was 
followed for three isolates (2, 8, and 16). Overnight bacterial 
cultures were suspended in 100 mL of autoclaved natural sea-
water. Bacterial suspensions were incubated at 20°C with 170 
rpm during 50 days of monitoring. After specified period of 
time, bottles were shaken, sub-samples were diluted in sterile 
saline solution, inoculated onto Nutrient agar plates, and bacte-
rial colonies were counted after incubation at 42°C/24h. Num-
ber of viable bacteria was determined as colony forming units 
(CFU), logarithmically transformed, and expressed as log CFU 
per 1 mL of seawater. Experiments were performed in technical 
triplicate with mean values presented. Survival of bacteria was 
calculated as ((logCFU/mLtime : logCFU/mLstart)*100), where 
log CFU/mLtime represents the number of bacteria on a day of 
measurement and log CFU/mLstart the initial number of bacteria.
Results
During the examination period, 10 isolates of A. baumannii 
were recovered from hospital wastewater and 4 from hospital-
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ized patients. MALDI-TOF MS analysis of all isolates gave the 
reliable score values above 2.0, identifying them as A. bauman-
nii. All 14 isolates displayed a high level of resistance (Table 1) 
to both carbapenems (imipenem and meropenem) with MICs 
>64 mg/L, and susceptibility to colistin (MIC<0.5 mg/L) and 
some of them to ampicillin/sulbactam (MIC 8-16 mg/L). The 
resistance phenotype was very similar for all isolates (resistant 
to carbapenems and the majority of tested antibiotics). Accord-
ing to the PFGE analysis (Fig. 1) 9 isolates were grouped in 4 
clusters with a similarity of at least 95% and they were selected 
for further molecular characterization. We also chose strain 2A 
for further analysis since it turned out that it was not in the same 
cluster with isolate 2. Four clinical isolates (c.i.13-16) from res-
piratory samples (BAL and tracheal aspirates) from patients in 
intensive care units of UHS were molecular analysed by PFGE 
Table 1. Phenotypic and genotyping characteristics of carbapenem-resistant isolates of A. baumannii recovered from hospital wastewater and clinical isolates 
from patients hospitalised in the University Hospital of Split
Number of Isolate (all) Resistance phenotipe Genotype Sampling
2,4,7,9
c.i.16
AB, IP, MP, AK, TB, 
 GM, CP, LV, SXT
bla OXA-51, bla OXA-23
OCT-15 
JAN-16 
3,6,8,11,12
c.i. 13,14,15
IP, MP, AK, GN,  
CP, LV, SXT
bla OXA-51, bla OXA-40
OCT-15, FEB-16
DEC-15, MAR-16 
AB, ampicillin-sulbactam; AK, amikacin; IP, imipenem; MP, meropenem; GM, gentamicin; TB, tobramicin; CP, ciprofloxacin; LV, levofloxacin; SXT, trimeth-
oprim/sulfamethoxazole; JAN, January; FEB, February; MAR, March; OCT, October; DEC, December; 15, 2015; 16, 2016; c.i. clinical isolate
Fig. 1. Results of genotyping by pulsed-field gel electrophoresis (PFGE) from 
wastewater isolates (1-12) and clinical isolates (13-16) of Acinetobacter bau-
mannii. The majority of isolates (9/10) were grouped in 4 clusters with a sim-
ilarity of at least 95%. 
Fig. 2. Multiplex PCR results from wastewater isolates (2-12) and clinical 
isolates (13-16) with positive controls (K1-3). In wastewater isolate 1 only bla 
OXA-51-like gen was detected. 
Fig. 3. Neighbour-joining phylogenetic tree inferred on blaOXA genes fragments 
amplified from wastewater isolates (2-12) and clinical isolates (13-16) of Acine-
tobacter baumannii. GenBank accession numbers are given next to the name 
of each strain.
and multiplex PCR together with wastewater isolates. Pheno-
typic and genotyping characteristics of carbapenem-resistant 
isolates of A. baumannii recovered from hospital wastewater 
and clinical isolates from patients hospitalised in the University 
Hospital of Split are presented in Table1. 
Multiplex PCR confirmed that besides from the fact that all 
isolates were positive for OXA-51-like genes, wastewater isolates 
2, 4, 7 and 9 harboured blaOXA-23-like , while wastewater isolates 
3, 6, 8, 11 and 12 harboured blaOXA-40-like genes (Fig. 2). Clinical 
isolates 13-15 harboured blaOXA-40-like and clinical isolate 16 blaOXA-
23-like gene. Phylogenetic analyses of all amplified and sequenced 
blaOXA fragments clearly supported the affiliation of detected 
blaOXA genes to two different clusters identical as those from clini-
cal isolates (c.i.13-16) and available in GenBank (Fig. 3). Clinical 
(13-15) and wastewater isolates 3, 6, 8, 11 and 12 shared 100% 
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sequence identity with blaOXA-72 sequence described in the same 
hospital in 2009, confi rming the presence of an endemic cluster. 
Three isolates of A. baumannii survived in seawater during 
50 days of monitoring (Fig.4). No multiplication of bacteria was 
observed as compared to initial numbers. After 7 days of contact, 
a decrease in bacterial numbers was observed up to 28 days, 
but there was no further sharp decrease up to 50 days of con-
tact. After 50 days in seawater, survival of A. baumannii isolates 
ranged from 55-67%, corresponding to 3.8-4.5 log CFU/mL.
Discussion
The epidemiology of emerging hospital pathogen A. baumannii 
still remains unclear even though numerous studies have investi-
gated nosocomial outbreaks during the last two decades [1, 20]. 
Unfortunately together with unclear epidemiology, the overuse of 
carbapenems has rapidly resulted in the worldwide dissemination 
of carbapenem resistant A. baumannii strain, including Croatia. 
In the last decade, drastic increase in resistance rate of carbap-
enem-resistant A. baumannii isolates is not isolated problem in 
only one hospital, but is already a leading national health problem 
requiring wider attention. Once endemic in the hospital setting, 
A. baumannii has become extremely diffi cult to eradicate [20]. 
Carbapenem resistant A. baumannii carrying OXA-72 oxacillinase 
spread in the UHS after transfer of a patient colonized by interna-
tional clonal lineage II (IC II) strain from General Hospital Mostar 
(Bosnia and Herzegovina) to the UHS at the beginning of 2009 
[8, 9]. Clinical isolates 13-15 in this study shared 100% sequence 
identity with the blaOXA-72 sequence described in the same hos-
pital in 2009, confi rming the presence of an endemic cluster. Since 
OXA-72 within OXA-40-like group was described as dominant 
mechanism of resistance in clinical isolates of A. baumannii in 
2009 inside UHS, this investigation also revealed oxacillinase 
belonging to OXA-23-like group (c.i.16) which contributed to the 
resistance rate to carbapenems of 90% in the last two years in 
UHS. Carbapenem resistance in A. baumannii has rapidly spread 
throughout Croatia since 2008 and high rates of non-susceptibil-
ity to imipenem (87%) and meropenem (88%) are unfortunately 
not unexpected [16]. The mechanism of carbapenem resistance in 
other hospitals in Croatia was similar as previously described in 
UHS from 2002 to 2008, and during 2009 [21].
The observation of multiresistant A. baumannii in hospital 
wastewater has also been previously reported in Brazil, Chi-
na and Zagreb in Croatia [6, 22, 23]. In Croatia, carbapenem 
resistant isolates of A. baumannii were detected in municipal 
wastewater treatment plant in capital city of Zagreb during 
2014 [13]. This fi nding has prompted several more research-
es including this one, focused on transmission of carbapenem 
resistant clinical isolates through the hospital wastewater into 
natural environment [10, 17]. In addition, the fi rst pan drug-re-
sistant environmental isolate of A. baumannii was recovered 
from the effl uent of secondary treated municipal wastewater 
of the capital city of Zagreb in Croatia in 2015, harbouring 
plasmid-located bla OXA-23-like gene [11]. This knowledge reveals 
municipal wastewater as a potential epidemiological reservoir 
of carbapenem resistant genes. The situation with wastewaters 
of UHS is even more complex since they are being released to 
the Adriatic Sea, without any pre-treatment.
Although three isolates of A. baumannii selected in this study 
did not multiply in seawater, they successfully survived in vitro 
investigation which lasted 50 days. The absence of bacterial 
multiplication could be explained by low nutrient concentration 
in natural seawater. In case that MDR A. baumannii reaches the 
seawater, it could be disseminated by sea current through the 
large area of the seawater ecosystem, which poses a serious 
public health concern. In Croatia, but also in great number of 
European countries, it is not legally required to treat hospital 
wastewater before discharging into the sewage system. Survival 
in the environmental conditions, including seawater especially 
in the warm period of the year up to 50 days, may also pose 
a potential epidemiological reservoir of carbapenem resistant 
genes. To the best of our knowledge, this is the fi rst description 
of transmission of carbapenem-resistant A. baumannii trough 
the hospital wastewater in this geographic area and monitoring 
of its survival in natural seawater. Our results suggest that the 
nosocomial pathogen A. baumannii is well adapted to different 
environments, not only to the hospital setting. 
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Fig. 4. Survival of A. baumannii wastewater isolates 2 and 8, and clinical iso-
late16 in seawater during 50 days of monitoring. Initial log CFU/mL: 6.7±0.1 
isolate 2; 7.3±0.1 isolate 8; 6.8±0.1 isolate 16. Survival of bacteria was cal-
culated as ((logCFU/mLtime : logCFU/mLstart)*100), where log CFU/mLtime is 
number of bacteria on day of measurement and log CFU/mLstart is initial number 
of bacteria. Mean values and standard deviations are presented. 
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